Announced Fri, 19 Jun · 21:11 IST
US FDA inspection at Eugia Steriles ends with 5 observations, no impact stated
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.4%1-day move
₹1499.50
prior close
₹1498.20
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2+0.3+0.3+0.4+2.4+2.1+3.7+2.6+5.0+4.2+3.5+2.2——
Up moveDown movePending
AI summary
US FDA conducted a Pre-Approval Inspection (PAI) at Aurobindo Pharma's stepdown subsidiary Eugia Steriles in Andhra Pradesh from June 10 to June 19, 2026. The inspection concluded with 5 observations, which the company will respond to within the stipulated time. Aurobindo stated there is no impact on financials or operations from this inspection.
Likely market impact
5 observations is manageable and common, but any FDA follow-up such as a Form 483 or warning letter could affect future product approvals and US revenue.